Loqir personal page - To The Moon

Loqir

Loqir

No personal profile

118Follow

0Followers

0Topic

0Badge

2021-06-07

A

Sorry, the original content has been removed

2021-05-20

A

Sorry, the original content has been removed

2021-04-21

It depends

Will Regeneron's COVID Cocktail Win Be Short-Lived?

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3575628371697362","uuid":"3575628371697362","gmtCreate":1612536765782,"gmtModify":1619003089893,"name":"Loqir","pinyin":"loqir","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/976eabb1a57844062c23a691d65a6743","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":118,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.11.03","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.23","exceedPercentage":"60.95%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.35%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":114880381,"gmtCreate":1623065313343,"gmtModify":1704195306537,"author":{"id":"3575628371697362","authorId":"3575628371697362","name":"Loqir","avatar":"https://static.tigerbbs.com/976eabb1a57844062c23a691d65a6743","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575628371697362","authorIdStr":"3575628371697362"},"themes":[],"htmlText":"A","listText":"A","text":"A","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/114880381","repostId":"2141286115","repostType":4,"repost":{"id":"2141286115","kind":"highlight","pubTimestamp":1623052500,"share":"https://ttm.financial/m/news/2141286115?lang=&edition=fundamental","pubTime":"2021-06-07 15:55","market":"us","language":"en","title":"3 Robinhood Stocks That Could Make You a Lot Richer Than AMC Will","url":"https://stock-news.laohu8.com/highlight/detail?id=2141286115","media":"Motley Fool","summary":"The long-term prospects look much brighter for these great companies.","content":"<p>There's a good reason why <b>AMC Entertainment</b> ranks as the third most popular stock for Robinhood investors. Shares of the theater chain have skyrocketed more than 2,500% so far this year. Most of those gains have come over the last few weeks.</p><p>Investors are deluding themselves if they think that kind of momentum for AMC is sustainable. However, there are other popular Robinhood stocks that do have attractive growth prospects. Here are three Robinhood stocks that could make you a lot richer than AMC will going forward.</p><p><img src=\"https://static.tigerbbs.com/8615f62a24d693e4bc1bbaeadc93a39c\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h2><a href=\"https://laohu8.com/S/FB\">Facebook</a></h2><p>Don't believe for <a href=\"https://laohu8.com/S/AONE\">one</a> second that lots of people have thrown in the towel on&nbsp;<b>Facebook</b> (NASDAQ:FB). The social media giant's number of monthly active users has continued to climb, topping 2.85 billion in the first quarter of 2021. Meanwhile, the number of frequent moviegoers -- AMC's prime customers -- was slipping in 2019 before anyone had ever heard of COVID-19.</p><p>Facebook is working hard to build a trillion-dollar empire. One key component of this effort is to continue attracting users to its social media platforms so that it can sell more ads. However, the company isn't just focused on social media. CEO Mark Zuckerberg highlighted three areas in Facebook's Q1 update that could be massive growth drivers in the future -- augmented and virtual reality (AR/VR), commerce, and the \"creator economy.\"</p><p>The company is already a leader in VR with its Oculus devices. Facebook and Ray-Ban have first-generation AR smart glasses on the way. It's also developing new devices including haptic gloves plus a virtual world called Horizon. Zuckerberg thinks that AR and VR will \"unlock a massive amount of value\" over time.</p><p>As for e-commerce, more than 1 billion people already visit Facebook Marketplace each month. Facebook recently launched Shops, an online storefront platform that has more than 250 million monthly visitors. The company is also developing a platform and tools that support the creator economy, including options for content creators to monetize their offerings.</p><h2>Moderna</h2><p><b>Moderna</b> (NASDAQ:MRNA) stands as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the key reasons why AMC could see its fortunes improve in 2021. The COVID-19 vaccine developed by Moderna has been given to millions of Americans and remains one of only three vaccines to secure U.S. Emergency Use Authorization so far.</p><p>As of its Q1 update in early May, Moderna had advanced purchase agreements in place for its COVID-19 vaccine totaling more than $19 billion. Since then, the company has picked up additional supply deals.</p><p>Moderna seems likely to make even more money next year than it will in 2021. Beyond 2022, the company anticipates that emerging coronavirus variants will result in the need for annual vaccinations.</p><p>But is all of this growth already priced into the biotech stock? Nope. Moderna's shares currently trade at only nine times expected earnings. With plenty of other pipeline candidates based on its messenger RNA technology potentially on the way, Moderna could easily make investors who hold on for the long run much richer.</p><h2>Square</h2><p>Like AMC,&nbsp;<b>Square</b> (NYSE:SQ) should directly benefit from the reopening of the U.S. economy. The company's seller ecosystem serves many small and medium-sized businesses that were hurt by the COVID-19 pandemic.</p><p>Square will likely be in a position to offer these business customers even more value going forward. It plans to introduce business checking and savings accounts, according to a recent Bloomberg report. This move isn't surprising, as Square hasn't made a secret of its desire to transition into banking services.</p><p>The company's biggest growth driver, though, is its Cash App ecosystem. Cash App currently supports a wide range of features, including peer-to-peer payments, a credit card, and buying and selling stocks and <b>Bitcoin</b>.</p><p>Probably the biggest knock against Square is its valuation. The stock trades at more than 150 times expected earnings. That valuation is still more attractive than AMC's, though. More importantly, the shift to a cashless society seems unstoppable. Square's growth prospects for both its seller and Cash App ecosystems make a premium price worth paying.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Robinhood Stocks That Could Make You a Lot Richer Than AMC Will</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Robinhood Stocks That Could Make You a Lot Richer Than AMC Will\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 15:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/06/3-robinhood-stocks-that-could-make-you-a-lot-riche/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There's a good reason why AMC Entertainment ranks as the third most popular stock for Robinhood investors. Shares of the theater chain have skyrocketed more than 2,500% so far this year. Most of those...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/06/3-robinhood-stocks-that-could-make-you-a-lot-riche/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","SQ":"Block"},"source_url":"https://www.fool.com/investing/2021/06/06/3-robinhood-stocks-that-could-make-you-a-lot-riche/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2141286115","content_text":"There's a good reason why AMC Entertainment ranks as the third most popular stock for Robinhood investors. Shares of the theater chain have skyrocketed more than 2,500% so far this year. Most of those gains have come over the last few weeks.Investors are deluding themselves if they think that kind of momentum for AMC is sustainable. However, there are other popular Robinhood stocks that do have attractive growth prospects. Here are three Robinhood stocks that could make you a lot richer than AMC will going forward.Image source: Getty Images.FacebookDon't believe for one second that lots of people have thrown in the towel on Facebook (NASDAQ:FB). The social media giant's number of monthly active users has continued to climb, topping 2.85 billion in the first quarter of 2021. Meanwhile, the number of frequent moviegoers -- AMC's prime customers -- was slipping in 2019 before anyone had ever heard of COVID-19.Facebook is working hard to build a trillion-dollar empire. One key component of this effort is to continue attracting users to its social media platforms so that it can sell more ads. However, the company isn't just focused on social media. CEO Mark Zuckerberg highlighted three areas in Facebook's Q1 update that could be massive growth drivers in the future -- augmented and virtual reality (AR/VR), commerce, and the \"creator economy.\"The company is already a leader in VR with its Oculus devices. Facebook and Ray-Ban have first-generation AR smart glasses on the way. It's also developing new devices including haptic gloves plus a virtual world called Horizon. Zuckerberg thinks that AR and VR will \"unlock a massive amount of value\" over time.As for e-commerce, more than 1 billion people already visit Facebook Marketplace each month. Facebook recently launched Shops, an online storefront platform that has more than 250 million monthly visitors. The company is also developing a platform and tools that support the creator economy, including options for content creators to monetize their offerings.ModernaModerna (NASDAQ:MRNA) stands as one of the key reasons why AMC could see its fortunes improve in 2021. The COVID-19 vaccine developed by Moderna has been given to millions of Americans and remains one of only three vaccines to secure U.S. Emergency Use Authorization so far.As of its Q1 update in early May, Moderna had advanced purchase agreements in place for its COVID-19 vaccine totaling more than $19 billion. Since then, the company has picked up additional supply deals.Moderna seems likely to make even more money next year than it will in 2021. Beyond 2022, the company anticipates that emerging coronavirus variants will result in the need for annual vaccinations.But is all of this growth already priced into the biotech stock? Nope. Moderna's shares currently trade at only nine times expected earnings. With plenty of other pipeline candidates based on its messenger RNA technology potentially on the way, Moderna could easily make investors who hold on for the long run much richer.SquareLike AMC, Square (NYSE:SQ) should directly benefit from the reopening of the U.S. economy. The company's seller ecosystem serves many small and medium-sized businesses that were hurt by the COVID-19 pandemic.Square will likely be in a position to offer these business customers even more value going forward. It plans to introduce business checking and savings accounts, according to a recent Bloomberg report. This move isn't surprising, as Square hasn't made a secret of its desire to transition into banking services.The company's biggest growth driver, though, is its Cash App ecosystem. Cash App currently supports a wide range of features, including peer-to-peer payments, a credit card, and buying and selling stocks and Bitcoin.Probably the biggest knock against Square is its valuation. The stock trades at more than 150 times expected earnings. That valuation is still more attractive than AMC's, though. More importantly, the shift to a cashless society seems unstoppable. Square's growth prospects for both its seller and Cash App ecosystems make a premium price worth paying.","news_type":1},"isVote":1,"tweetType":1,"viewCount":521,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3582854091383813","authorId":"3582854091383813","name":"J7821717","avatar":"https://static.tigerbbs.com/af3e42db26d8c0bcd55e8b1c86a6f8ac","crmLevel":2,"crmLevelSwitch":0,"idStr":"3582854091383813","authorIdStr":"3582854091383813"},"content":"Like and comment","text":"Like and comment","html":"Like and comment"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":130855033,"gmtCreate":1621525558122,"gmtModify":1704359154811,"author":{"id":"3575628371697362","authorId":"3575628371697362","name":"Loqir","avatar":"https://static.tigerbbs.com/976eabb1a57844062c23a691d65a6743","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575628371697362","authorIdStr":"3575628371697362"},"themes":[],"htmlText":"A","listText":"A","text":"A","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/130855033","repostId":"1114639105","repostType":4,"isVote":1,"tweetType":1,"viewCount":420,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":378382981,"gmtCreate":1619001463443,"gmtModify":1704718105534,"author":{"id":"3575628371697362","authorId":"3575628371697362","name":"Loqir","avatar":"https://static.tigerbbs.com/976eabb1a57844062c23a691d65a6743","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575628371697362","authorIdStr":"3575628371697362"},"themes":[],"htmlText":"It depends&nbsp;","listText":"It depends&nbsp;","text":"It depends","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/378382981","repostId":"2129875413","repostType":4,"isVote":1,"tweetType":1,"viewCount":402,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":114880381,"gmtCreate":1623065313343,"gmtModify":1704195306537,"author":{"id":"3575628371697362","authorId":"3575628371697362","name":"Loqir","avatar":"https://static.tigerbbs.com/976eabb1a57844062c23a691d65a6743","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575628371697362","authorIdStr":"3575628371697362"},"themes":[],"htmlText":"A","listText":"A","text":"A","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/114880381","repostId":"2141286115","repostType":4,"isVote":1,"tweetType":1,"viewCount":521,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3582854091383813","authorId":"3582854091383813","name":"J7821717","avatar":"https://static.tigerbbs.com/af3e42db26d8c0bcd55e8b1c86a6f8ac","crmLevel":2,"crmLevelSwitch":0,"idStr":"3582854091383813","authorIdStr":"3582854091383813"},"content":"Like and comment","text":"Like and comment","html":"Like and comment"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":130855033,"gmtCreate":1621525558122,"gmtModify":1704359154811,"author":{"id":"3575628371697362","authorId":"3575628371697362","name":"Loqir","avatar":"https://static.tigerbbs.com/976eabb1a57844062c23a691d65a6743","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575628371697362","authorIdStr":"3575628371697362"},"themes":[],"htmlText":"A","listText":"A","text":"A","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/130855033","repostId":"1114639105","repostType":4,"isVote":1,"tweetType":1,"viewCount":420,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":378382981,"gmtCreate":1619001463443,"gmtModify":1704718105534,"author":{"id":"3575628371697362","authorId":"3575628371697362","name":"Loqir","avatar":"https://static.tigerbbs.com/976eabb1a57844062c23a691d65a6743","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575628371697362","authorIdStr":"3575628371697362"},"themes":[],"htmlText":"It depends&nbsp;","listText":"It depends&nbsp;","text":"It depends","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/378382981","repostId":"2129875413","repostType":4,"repost":{"id":"2129875413","kind":"highlight","pubTimestamp":1619001180,"share":"https://ttm.financial/m/news/2129875413?lang=&edition=fundamental","pubTime":"2021-04-21 18:33","market":"us","language":"en","title":"Will Regeneron's COVID Cocktail Win Be Short-Lived?","url":"https://stock-news.laohu8.com/highlight/detail?id=2129875413","media":"Motley Fool","summary":"The biotech's antibody therapy continues to show promise. But there's considerable uncertainty about its long-term prospects.","content":"<p><b><a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a></b> (NASDAQ:REGN) recently racked up a couple of additional successes with late-stage studies of its COVID-19 antibody cocktail REGEN-COV.&nbsp;In this <i>Motley Fool Live</i> video <b>recorded on April 14, 2021</b>, Motley Fool contributors Keith Speights and Brian Orelli discuss whether the biotech's COVID cocktail win will only be short-lived.</p><p><b>Keith Speights:</b> Regeneron Pharmaceuticals, the ticker there is REGN, had two positive announcements for its COVID-19 antibody cocktail, REGEN-COV. They announced both of these new developments on Monday.</p><p>The company reported results from a late-stage study that showed that this antibody cocktail significantly reduced progression to symptomatic COVID-19 in patients who had been recently infected. It also announced results from another phase 3 study that showed the antibody cocktail reduced the risk of infection for individuals in households where another person had been infected by the coronavirus.</p><p>These are definitely positive stories for Regeneron, but do you think these wins will translate to significant revenue for the biotech? Or could these wins actually be short-lived?</p><p><b>Brian Orelli:</b> Obviously as more and more people get vaccinated the infection rates should go down, and then therefore the opportunity to treat people either prophylactically because they've been exposed or because they realized that they test positive but don't have any symptoms and then want this antibody cocktail, that opportunity is going to be go down, but it's not going to go to zero, and so I think there's an opportunity for some treatments.</p><p>But certainly the market for treatments is going to diminish substantially over the next few months and into the next year. I don't know.</p><p>The other wildcard here is the variance. The variance pop up and we can't keep up fast enough with them, and they are infecting enough people that are already vaccinated and we can't keep up creating new vaccine fast enough, then I think that's another opportunity for the treatments that they don't have right now.</p><p><b>Speights:</b> I think that's a really good take on it, Brian. If you're looking at potentially investing in Regeneron, there are other reasons to consider buying the stock. I think you said recently, Brian, that they just don't fail. [laughs] Has Regeneron had any failures? [laughs] Not recently.</p><p><b>Orelli:</b> Not late-stage failure certainly. I can't think of any failures that they've had.</p><p><b>Speights:</b> The company has several drugs with fast-growing sales. This is obviously promising news with this antibody therapy. But like you say, Brian, it remains to be seen whether or not it's going to have market traction over the long run. It's hard to say. It's hard to say what's going to happen in the world of COVID-19 beyond the pandemic.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Will Regeneron's COVID Cocktail Win Be Short-Lived?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWill Regeneron's COVID Cocktail Win Be Short-Lived?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-21 18:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/21/will-regenerons-covid-cocktail-win-be-short-lived/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Regeneron Pharmaceuticals (NASDAQ:REGN) recently racked up a couple of additional successes with late-stage studies of its COVID-19 antibody cocktail REGEN-COV. In this Motley Fool Live video recorded...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/21/will-regenerons-covid-cocktail-win-be-short-lived/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司"},"source_url":"https://www.fool.com/investing/2021/04/21/will-regenerons-covid-cocktail-win-be-short-lived/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2129875413","content_text":"Regeneron Pharmaceuticals (NASDAQ:REGN) recently racked up a couple of additional successes with late-stage studies of its COVID-19 antibody cocktail REGEN-COV. In this Motley Fool Live video recorded on April 14, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether the biotech's COVID cocktail win will only be short-lived.Keith Speights: Regeneron Pharmaceuticals, the ticker there is REGN, had two positive announcements for its COVID-19 antibody cocktail, REGEN-COV. They announced both of these new developments on Monday.The company reported results from a late-stage study that showed that this antibody cocktail significantly reduced progression to symptomatic COVID-19 in patients who had been recently infected. It also announced results from another phase 3 study that showed the antibody cocktail reduced the risk of infection for individuals in households where another person had been infected by the coronavirus.These are definitely positive stories for Regeneron, but do you think these wins will translate to significant revenue for the biotech? Or could these wins actually be short-lived?Brian Orelli: Obviously as more and more people get vaccinated the infection rates should go down, and then therefore the opportunity to treat people either prophylactically because they've been exposed or because they realized that they test positive but don't have any symptoms and then want this antibody cocktail, that opportunity is going to be go down, but it's not going to go to zero, and so I think there's an opportunity for some treatments.But certainly the market for treatments is going to diminish substantially over the next few months and into the next year. I don't know.The other wildcard here is the variance. The variance pop up and we can't keep up fast enough with them, and they are infecting enough people that are already vaccinated and we can't keep up creating new vaccine fast enough, then I think that's another opportunity for the treatments that they don't have right now.Speights: I think that's a really good take on it, Brian. If you're looking at potentially investing in Regeneron, there are other reasons to consider buying the stock. I think you said recently, Brian, that they just don't fail. [laughs] Has Regeneron had any failures? [laughs] Not recently.Orelli: Not late-stage failure certainly. I can't think of any failures that they've had.Speights: The company has several drugs with fast-growing sales. This is obviously promising news with this antibody therapy. But like you say, Brian, it remains to be seen whether or not it's going to have market traction over the long run. It's hard to say. It's hard to say what's going to happen in the world of COVID-19 beyond the pandemic.","news_type":1},"isVote":1,"tweetType":1,"viewCount":402,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}